FOXP3 and neoplasm: For example, foxp3-expressing regulatory T cells (Treg) can inhibit anti-tumor immunity by releasing immune checkpoint proteins such as CD25 and CTLA-4 and are often associated with unfavorable outcomes in cancer patients [69].